Related Experiment Video

Updated: May 23, 2026

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

HDL-C levels and cardiovascular disease: more is not always better!

Santiago Mc Loughlin1, Gastón A Rodríguez-Granillo

  • 1Instituto de Investigaciones Cardiológicas Alberto C. Taquini (UBA-CONICET), Buenos Aires, Argentina. santimcl@gmail.com

Recent Patents on Cardiovascular Drug Discovery
|March 23, 2012
PubMed

Insights

Despite statin therapy, cardiovascular disease persists. This review explores high-density lipoprotein cholesterol (HDL-C) metabolism and patents, examining HDL-C-raising therapies for residual cardiovascular risk.

Area of Science:

  • Cardiology
  • Biochemistry
  • Pharmacology

Background:

  • Cardiovascular disease (CVD) remains a leading cause of mortality despite statin use.
  • A significant residual risk (approx. 70%) exists in patients on optimal anti-atherosclerotic therapies.
  • High-density lipoprotein cholesterol (HDL-C) levels are inversely correlated with CVD incidence.

Purpose of the Study:

  • To review the structure and metabolism of HDL-C.
  • To discuss patents related to HDL-C levels and CVD.
  • To explore the potential of HDL-C-increasing therapies for CVD prevention.

Main Methods:

  • Literature review focusing on HDL-C structure, metabolism, and relevant patents.
  • Analysis of existing data on HDL-C levels and cardiovascular risk.
  • Examination of clinical trial outcomes for HDL-C-raising therapies.

Main Results:

  • Statins provide significant risk reduction but leave residual risk.
  • HDL-C-C levels correlate inversely with CVD risk.
  • Pharmacological HDL-C increases have yielded conflicting results and some safety concerns.

Conclusions:

  • Alternative strategies are needed to address residual CVD risk.
  • Understanding HDL-C metabolism is crucial for developing new therapies.
  • The role of HDL-C-increasing therapies in primary and secondary CVD prevention requires further investigation.

More Related Videos

Evaluation of Hydration Status by Bioelectrical Impedance Vector Analysis in Patients with Ischemic Heart Disease Undergoing Exercise Stress Test10:21

Evaluation of Hydration Status by Bioelectrical Impedance Vector Analysis in Patients with Ischemic Heart Disease Undergoing Exercise Stress Test

Published on: September 22, 2023

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...